Lisinopril and Hydrochlorothiazide Tablets (20+25) mg + Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting
Conditions
Fasting
Trial Timeline
Oct 1, 2012 → Oct 1, 2012
NCT ID
NCT01831700About Lisinopril and Hydrochlorothiazide Tablets (20+25) mg + Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Lisinopril and Hydrochlorothiazide Tablets (20+25) mg + Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets is a phase 1 stage product being developed by Ipca Laboratories for Fasting. The current trial status is completed. This product is registered under clinical trial identifier NCT01831700. Target conditions include Fasting.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01831700 | Phase 1 | Completed |
| NCT01827878 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting